Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 9, 2012, Pages 697-703

  Karlson, B W ^a,b   Barter, P J ^c   Palmer, M K ^d   Lundman, P ^e   Nicholls, S J ^f  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c HEART RESEARCH INSTITUTE   (Australia)

^d KEELE UNIVERSITY   (United Kingdom)

^e DANDERYD HOSPITAL   (Sweden)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atorvastatin; Cholesterol, LDL; Diabetes mellitus; Hydroxymethylglutaryl CoA reductase inhibitors; Meta analysis; Rosuvastatin; Simvastatin

Indexed keywords

ATORVASTATIN; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; SULFONAMIDE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DIABETES MELLITUS; DOSE RESPONSE; FACTUAL DATABASE; FEMALE; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DATABASES, FACTUAL; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; SULFONAMIDES; TRIGLYCERIDES; YOUNG ADULT;

EID: 84865710739     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.03.003     Document Type: Article

References (28)

1. Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in Adults. Executive summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
3. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
4. American Diabetes Association Standards of Medical Care in Diabetes-2006. Diabetes Care 2006, 29(Suppl. 1):s4-s42.
5. Buse J.B., Ginsberg H.N., Bakris G.L., Clark N.G., Costa F., Eckel R., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114-126.
6. Holman R.R., Paul S.K., Bethel M.A., Neil H.A., Matthews D.R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008, 359:1565-1576.
7. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the study of diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136.
8. Delahoy P.J., Magliano D.J., Webb K., Grobler M., Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 2009, 31:236-244.
9. Rahilly-Tierney C.R., Lawler E.V., Scranton R.E., Gaziano J.M. Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age. Circulation 2009, 120:1491-1497.
10. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
11. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
12. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
13. Opie L.H., Commerford P.J., Gersh B.J. Controversies in stable coronary artery disease. Lancet 2006, 367:69-78.
14. Jacobs-van der Bruggen M.A.M., Engelfriet P.M., Hoogenveen R.T., van Baal P.H., Struijs J.N., Verschuren W.M., et al. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands. Eur J Cardiovasc Prev Rehabil 2008, 15:521-525.
15. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
16. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-S113.
17. Berne C., Siewert-Delle A. URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005, 4:7.
18. Wolffenbuttel B.H., Franken A.A., Vincent H.H. Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Intern Med 2005, 257:531-539.
19. Betteridge D.J., Gibson J.M. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med 2007, 24:541-549.
20. Nicholls S.J., Brandrup-Wognsen G., Palmer M., Barter P.J. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010, 105:69-76.
21. Brown H., Prescott R. Applied mixed models in medicine 2006, John Wiley and Sons Ltd., Chichester. 2nd ed.
22. Barter P.J., Brandrup-Wognsen G., Palmer M.K., Nicholls S.J. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010, 51:1546-1553.
23. Collins R., Armitage J., Parish S., Sleigh P., Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
24. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
25. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220-1226.
26. Leiter L.A., Betteridge D.J., Chacra A.R., Chait A., Ferrannini E., Haffner S.M., et al. AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2006, 6:31-40.
27. Banegas J.R., López-García E., Dallongeville J., Guallar E., Halcox J.P., Borghi C., et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011, 32:2143-2152.
28. Joseph J., Svartberg J., Njølstad I., Schirmer H. Change in cardiovascular risk factors in relation to diabetes status: the Tromsø study. Eur J Cardiovasc Prev Rehabil 2011, [Epub ahead of print]. 10.1177/1741826711408147.